In the past week, CDXC stock has gone down by -6.61%, with a monthly decline of -4.41% and a quarterly surge of 113.82%. The volatility ratio for the week is 9.03%, and the volatility levels for the last 30 days are 7.00% for Chromadex Corp The simple moving average for the last 20 days is -7.66% for CDXC’s stock, with a simple moving average of 63.82% for the last 200 days.
Is It Worth Investing in Chromadex Corp (NASDAQ: CDXC) Right Now?
The stock has a 36-month beta value of 1.91. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CDXC is 48.42M, and at present, short sellers hold a 3.35% of that float. On May 24, 2024, the average trading volume of CDXC was 362.33K shares.
CDXC) stock’s latest price update
Chromadex Corp (NASDAQ: CDXC)’s stock price has soared by 2.52 in relation to previous closing price of 3.17. Nevertheless, the company has seen a loss of -6.61% in its stock price over the last five trading days. businesswire.com reported 2024-05-23 that LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event. To arrang.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at -7.59% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.11% of loss for the given period.
Volatility was left at 7.00%, however, over the last 30 days, the volatility rate increased by 9.03%, as shares sank -4.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +54.76% upper at present.
During the last 5 trading sessions, CDXC fell by -6.61%, which changed the moving average for the period of 200-days by +95.78% in comparison to the 20-day moving average, which settled at $3.51. In addition, Chromadex Corp saw 127.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Gerber Brianna, who purchase 5,000 shares at the price of $1.41 back on Dec 01 ’23. After this action, Gerber Brianna now owns 27,436 shares of Chromadex Corp, valued at $7,050 using the latest closing price.
Jaksch Frank L Jr, the Director of Chromadex Corp, purchase 7,000 shares at $1.69 during a trade that took place back on Jun 12 ’23, which means that Jaksch Frank L Jr is holding 231,339 shares at $11,830 based on the most recent closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- -0.04 for the present operating margin
- 0.61 for the gross margin
The net margin for Chromadex Corp stands at -0.04. The total capital return value is set at -0.09. Equity return is now at value -12.39, with -6.54 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 1.41. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 49.42.
Currently, EBITDA for the company is -0.19 million with net debt to EBITDA at 15.15. When we switch over and look at the enterprise to sales, we see a ratio of 2.66. The receivables turnover for the company is 11.08for trailing twelve months and the total asset turnover is 1.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.52.
Conclusion
To sum up, Chromadex Corp (CDXC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
